Very severe hypertriglyceridemia in a subject with poor glycemic control: a case report with general consideration

Main Article Content

E. Xhardo
F. Agaçi

Abstract

Hypertriglyceridemia is defined as a value of fasting serum triglyceride over 150 mg/dl. The classification of hypertriglyceridemia according to the Endocrine Society includes mild and moderate hypertriglyceridemia, severe hypertriglyceridemia and very severe hypertriglyceridemia. Mild and moderate hypertriglyceridemia increases the risk for cardiovascular events while severe and very severe hypertriglyceridemia is a risk factor for acute pancreatitis. Conventional pharmacological therapy of hypertriglyceridemia includes fibrates, niacin, statins, ezetimibe, and omega-3 fatty acid. Other triglyceride-lowering therapies are represented by plasmapheresis and lipoprotein lipase gene therapy. The present work refers to a 55-year-old man without a history of family diabetes mellitus (DM), dyslipidemia, premature coronary artery disease, diagnosed with type 2 DM in 2016, from 2018 on insulin treatment; he was hospitalized for endocrine evaluation. The patient had a history of high blood pressure for approximately 15 years, chronic kidney disease, very severe hypertriglyceridemia, and chronic obstructive pulmonary disease. The patient followed treatment with hypoglycemic, hypolipemic, low-salt diet, fibrates, statins, omega-3 fatty acid.

Article Details

How to Cite
Xhardo, E., and F. Agaçi. “Very Severe Hypertriglyceridemia in a Subject With Poor Glycemic Control: A Case Report With General Consideration”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 2, Mar. 2020, pp. 168-71, doi:10.22141/2224-0721.16.2.2020.201304.
Section
Clinical Case

References

Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969–2989. doi:10.1210/jc.2011-3213.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497. doi:10.1001/jama.285.19.2486.

Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113–1120. doi:10.1503/cmaj.060963.

Bouabdellah M, Iraqi H, Benlian P, et al. Familial hypertriglyceridemia: biochemical, clinical and molecular study in a Moroccan family. Ann Biol Clin (Paris). 2015;73(4):474–484. doi:10.1684/abc.2015.1058. (in French).

Bainton D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J. 1992;68(1):60–66. doi:10.1136/hrt.68.7.60.

Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med. 2002;2(3):325–333. doi:10.1055/s-2002-35403.

Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110(17):2678–2686. doi:10.1161/01.CIR.0000145615.33955.83.

Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med. 2007;147(6):377–385. doi:10.7326/0003-4819-147-6-200709180-00007.

Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213–219.

Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009;24(4):345–350. doi:10.1097/HCO.0b013e32832c1284.

Gan SI, Edwards AL, Symonds CJ, Beck PL. Hypertriglyceridemia-induced pancreatitis: A case-based review. World J Gastroenterol. 2006;12(44):7197–7202. doi:10.3748/wjg.v12.i44.7197.

Yang F, Wang Y, Sternfeld L, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol (Oxf). 2009;195(1):13–28. doi:10.1111/j.1748-1716.2008.01933.x.

Sztefko K, Panek J. Serum free fatty acid concentration in patients with acute pancreatitis. Pancreatology. 2001;1(3):230–236. doi:10.1159/000055816.

de Beaux AC, Ross JA, Maingay JP, Fearon KC, Carter DC. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis. Br J Surg. 1996;83(8):1071–1075. doi:10.1002/bjs.1800830811.

Kuśnierz-Cabala B, Gurda-Duda A, Dumnicka P, et al. Analysis of selected inflammatory markers for early prediction of severe clinical course of acute pancreatitis. Przegl Lek. 2013;70(6):392–396. (in Polish).

Kota SK, Kota SK, Jammula S, Krishna SV, Modi KD. Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review. Indian J Endocrinol Metab. 2012;16(1):141–143. doi:10.4103/2230-8210.91211.

Barter PJ, Rye KA. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?. Circulation. 2006;113(12):1553–1555. doi:10.1161/CIRCULATIONAHA.105.620450.

Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94–114. doi:10.1111/j.1365-2796.2005.01528.x.

Bays H. Ezetimibe. Expert Opin Investig Drugs. 2002;11(11):1587–1604. doi:10.1517/13543784.11.11.1587.

Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ. 2006;332(7544):752–760. doi:10.1136/bmj.38755.366331.2F.

Shearer GC, Savinova OV, Harris WS. Fish oil -- how does it reduce plasma triglycerides?. Biochim Biophys Acta. 2012;1821(5):843–851. doi:10.1016/j.bbalip.2011.10.011.